News
Oval Medical expands with two new hires
Monday, 18 July 2011 -The autoinjector development company Oval Medical Technologies ltd, has today announced further expansion with two new appointments of a Programme Manager and a Design Engineer. Alison…
Read MoreOval signs two feasibility deals with pharmaceutical companies
11th April 2011 – Oval Medical Technologies Ltd., the company developing the next generation of autoinjector technology, announced today that they have entered into two deals with pharmaceutical companies who…
Read MoreNext generation autoinjector shows clear superiority
10th January 2011 – Oval Medical Technologies Ltd., the Cambridge based autoinjector company today announced results from two user studies in which Oval’s novel, proprietary autoinjector clearly demonstrated superiority compared…
Read MoreCatherine Beech interviewed by the Cambridge Evening News
Dr. Catherine Beech talks with Business Editor Jenny Chapman. ‘He’s one of those people who can see a better way of doing things, to make them more useful,” says Dr…
Read MoreOval Medical featured in ONdrugDELIVERY
Oval Medical Technologies Limited is based in Cambridge and has broad expertise in design and development of drug delivery devices focusing on vials, prefilled syringes and autoinjectors. The company was…
Read MoreThree new employees appointed
27th July 2010 – Today, Oval Medical is pleased to announce that the on-going success of developing its revolutionary autoinjector and syringe technologies, has lead to the company’s second expansion…
Read MoreBusiness Weekly Feature: Interview with Matthew Young, Founder of Oval Medical Technologies
Oval Medical Technologies Limited is based in Cambridge and has broad expertise in design and development of drug delivery devices focusing on vials, prefilled syringes and autoinjectors. The company was…
Read MoreOval Medical signs a technology assessment contract with a pharmaceutical partner
February 12th, 2013 – Oval Medical Technologies Ltd.(“Oval”), announces that it has signed a further technology assessment contract with a pharmaceutical partner. The drug under investigation is for the treatment…
Read More